UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression

Journal of hematology and oncology, 2022-10, Vol.15 (1), p.1-144, Article 144

2022

Volltextzugriff (PDF)

The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway

Clinical cancer research, 2017-04, Vol.23 (7), p.1733-1747

2017

Volltextzugriff (PDF)

Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis

Clinical immunology (Orlando, Fla.), 2017-10, Vol.183, p.316-324

2017

Volltextzugriff (PDF)

Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F‐Benzoyl‐TN14003

Stem cells (Dayton, Ohio), 2007-09, Vol.25 (9), p.2158-2166

2007

Volltextzugriff (PDF)

In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non–small cell lung cancer

The Journal of thoracic and cardiovascular surgery, 2012-11, Vol.144 (5), p.1167-1175.e1

2012

Volltextzugriff (PDF)

Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response

Journal of Immunology, 2006-09, Vol.177 (6), p.4196-4202

2006

Volltextzugriff (PDF)

Promiscuous Chemokine Antagonist (BKT130) Suppresses Laser-Induced Choroidal Neovascularization by Inhibition of Monocyte Recruitment

Journal of Immunology Research, 2019, Vol.2019 (2019), p.1-12

2019

Volltextzugriff (PDF)

Interaction between CXCR4 and CCL20 pathways regulates tumor growth

PloS one, 2009-04, Vol.4 (4), p.e5125-e5125

2009

Volltextzugriff (PDF)

CDC25C Protein Expression Correlates with Tumor Differentiation and Clinical Outcomes in Lung Adenocarcinoma

Biomedicines, 2023-01, Vol.11 (2), p.362

2023

Volltextzugriff (PDF)

Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation

Frontiers in immunology, 2017-11, Vol.8, p.1432-1432

2017

Volltextzugriff (PDF)

In the Hunt for Therapeutic Targets: Mimicking the Growth, Metastasis, and Stromal Associations of Early-Stage Lung Cancer Using a Novel Orthotopic Animal Model

Journal of thoracic oncology, 2015-01, Vol.10 (1), p.46-58

2015

Volltextzugriff (PDF)

Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells

Journal of neuroimmunology, 2005-06, Vol.163 (1), p.157-164

2005

Volltextzugriff (PDF)

Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies

Cytokine (Philadelphia, Pa.), 2018-09, Vol.109, p.11-16

2018

Volltextzugriff (PDF)

The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells

Blood, 2021-11, Vol.138 (Supplement 1), p.2804-2804

2021

Volltextzugriff (PDF)

The role of IL‐18 and IL‐12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells

International immunology, 2002-12, Vol.14 (12), p.1449-1457

2002

Volltextzugriff (PDF)

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype

Oncotarget, 2014-11, Vol.5 (22), p.11283-11296

2014

Volltextzugriff (PDF)

CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways

Cancer research (Chicago, Ill.), 2018-03, Vol.78 (6), p.1471-1483

2018

Volltextzugriff (PDF)

The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

Clinical cancer research, 2014-01, Vol.20 (2), p.469-479

2014

Volltextzugriff (PDF)

WED-534 MiR122 expression regulates liver immune tolerance and microenvironment

Journal of hepatology, 2024-06, Vol.80, p.S278-S279

2024

Volltextzugriff (PDF)

Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo

Molecular cancer therapeutics, 2014-05, Vol.13 (5), p.1155-1169

2014

Volltextzugriff (PDF)

Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140

Clinical cancer research, 2013-07, Vol.19 (13), p.3495-3507

2013

Volltextzugriff (PDF)

Abstract 674: Novel anti-cancer small molecule targeting the protein regulator of cytokinesis pathway

Cancer research (Chicago, Ill.), 2024-03, Vol.84 (6_Supplement), p.674-674

2024

Volltextzugriff (PDF)

Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34 + Cells in Healthy Volunteers

Clinical cancer research, 2017-11, Vol.23 (22), p.6790-6801

2017

Volltextzugriff (PDF)

Inflammation‐induced hepatocellular carcinoma is dependent on CCR5 in mice

Hepatology (Baltimore, Md.), 2013-09, Vol.58 (3), p.1021-1030

2013

Volltextzugriff (PDF)

The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators

Biochemical pharmacology, 2019-10, Vol.168, p.412-428

2019

Volltextzugriff (PDF)

1 – 25 von 761

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(613)
Mit Volltextzugriff
(679)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(5)

Menü

Weitere Dienste

Einstellungen

CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression

The Sphingosine-1-Phosphate Modulator FTY720 Targets Multiple Myeloma via the CXCR4/CXCL12 Pathway

Natural and induced immunization against CCL20 ameliorate experimental autoimmune encephalitis and may confer protection against multiple sclerosis

Enhanced Unique Pattern of Hematopoietic Cell Mobilization Induced by the CXCR4 Antagonist 4F‐Benzoyl‐TN14003

In vitro and in vivo therapeutic efficacy of CXCR4 antagonist BKT140 against human non–small cell lung cancer

Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response

Promiscuous Chemokine Antagonist (BKT130) Suppresses Laser-Induced Choroidal Neovascularization by Inhibition of Monocyte Recruitment

Interaction between CXCR4 and CCL20 pathways regulates tumor growth

CDC25C Protein Expression Correlates with Tumor Differentiation and Clinical Outcomes in Lung Adenocarcinoma

Development of Novel Promiscuous Anti-Chemokine Peptibodies for Treating Autoimmunity and Inflammation

In the Hunt for Therapeutic Targets: Mimicking the Growth, Metastasis, and Stromal Associations of Early-Stage Lung Cancer Using a Novel Orthotopic Animal Model

Gelatinases (MMP-2 and MMP-9) are preferentially expressed by Th1 vs. Th2 cells

Role of CXCL12 and CXCR4 in the pathogenesis of hematological malignancies

The High Affinity CXCR4 Inhibitor, BL-8040, Impairs the Infiltration, Migration, Viability, and Differentiation of Regulatory T Cells

The role of IL‐18 and IL‐12 in the modulation of matrix metalloproteinases and their tissue inhibitors in monocytic cells

Multiple myeloma cells recruit tumor-supportive macrophages through the CXCR4/CXCL12 axis and promote their polarization toward the M2 phenotype

CXCR4 Promotes Neuroblastoma Growth and Therapeutic Resistance through miR-15a/16-1-Mediated ERK and BCL2/Cyclin D1 Pathways

The High-Affinity CXCR4 Antagonist BKT140 Is Safe and Induces a Robust Mobilization of Human CD34+ Cells in Patients with Multiple Myeloma

WED-534 MiR122 expression regulates liver immune tolerance and microenvironment

Combination of imatinib with CXCR4 antagonist BKT140 overcomes the protective effect of stroma and targets CML in vitro and in vivo

Targeting the CD20 and CXCR4 Pathways in Non-Hodgkin Lymphoma with Rituximab and High-Affinity CXCR4 Antagonist BKT140

Abstract 674: Novel anti-cancer small molecule targeting the protein regulator of cytokinesis pathway

Single Dose of the CXCR4 Antagonist BL-8040 Induces Rapid Mobilization for the Collection of Human CD34 + Cells in Healthy Volunteers

Inflammation‐induced hepatocellular carcinoma is dependent on CCR5 in mice

The mTOR inhibitor everolimus overcomes CXCR4-mediated resistance to histone deacetylase inhibitor panobinostat through inhibition of p21 and mitotic regulators

Suchergebnisse filtern